false 0001094038 0001094038 2024-06-06 2024-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


June 6, 2024

Date of Report (Date of earliest event reported)



(Exact name of registrant as specified in its charter)


Delaware 001-37939 45-4497941
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)


9350 Kirby Drive

Suite 300

Houston, Texas

(Address of principal executive offices)   (Zip Code)



Registrant’s telephone number, including area code



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading
  Name of each exchange on which registered
Common Stock, par value $0.001 per share   MRKR   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.07 Submission of Matters to a Vote of Security Holders.


On June 6, 2024, Marker Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The stockholders considered three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2024. Of the 8,913,490 shares outstanding as of the record date, 5,646,313 shares, or 63.35%, were present virtually or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.


Proposal No. 1: Election of five nominees to serve as directors until the 2025 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:


 Name  Votes For   Votes
David Eansor   3,038,468    183,932 
Steven Elms   3,068,548    153,852 
John Wilson   3,040,976    181,424 
Juan Vera   3,068,257    154,143 
Katharine Knobil   3,063,767    158,633 


Broker Non-Votes: 2,423,913.


All nominees were elected.


Proposal No. 2: Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The votes were cast as follows:


   Votes For   Votes
Advisory approval of named executive officer compensation   2,931,920    276,480    14,000 


Broker Non-Votes: 2,423,913.


Proposal No. 3: Ratification of the selection of Marcum LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: 


   Votes For   Votes
Ratification of appointment of Marcum LLP   5,137,819    494,128    14,366 


Broker Non-Votes: 0.


Item 8.01 Other Events.


On June 10, 2024, the Company provided notice of its termination of that certain Controlled Equity OfferingSM Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald & Co. and RBC Capital Markets, LLC, or the Sales Agents, pursuant to which the Company could offer and sell, from time to time at its discretion through the Sales Agents, shares of its common stock having an aggregate offering price of up to $75.0 million. (the “ATM Offering Program”). The Company is not subject to any termination penalties related to the termination of the ATM Agreement.  






Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No. Description
  104   Cover Page Interactive Data File (embedded within the Inline XBRL document).







Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Marker Therapeutics, Inc.
Dated: June 11, 2024 By: /s/ Juan Vera
    Juan Vera
    President and Chief Executive Officer